Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Sponsor
National Hospital Organization Nagoya Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04396457
Collaborator
Central Japan Lung Study Group (Other), Merck Sharp & Dohme LLC (Industry)
50
1
1
53.3
0.9

Study Details

Study Description

Brief Summary

To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion score (TPS) of less than 50%.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion score (TPS) of less than 50%.Primary endpoint is overall response rate and secondary endpoints are progression free survival (PFS), 1 year PFS rate, overall survival and adverse event.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%: CJLSG1901
Actual Study Start Date :
May 25, 2020
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pembrolizumab+Pemetrexed

200 mg of pembrolizumab is intravenously infused over 30 minutes and more on day 1. 500 mg/m^2 of pemetrexed is intravenously infused over 10 minutes and more on day 1. *Administration of folic acid and vitamin B12 is started 1 week before the start of treatment with pemetrexed. And repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit of the pembrolizumab administration is 35 cycles, and the pemetrexed administration will continue until the treatment cessation criteria are met.

Drug: Pembrolizumab
Human PD-1 Monoclonal antibody
Other Names:
  • KEYTRUDA Injection
  • Drug: Pemetrexed
    Antineoplastic antimetabolite
    Other Names:
  • Alimta Injection
  • Outcome Measures

    Primary Outcome Measures

    1. Overall response rate [Up to approximately 3 years]

    Secondary Outcome Measures

    1. Progression free survival [Up to approximately 3 years]

    2. 1 year progression free survival rate [1 year]

    3. Overall survival [Up to approximately 3 years]

    4. Adverse event [Up to approximately 3 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    75 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Non-squamous non-small cell lung cancer (NSCLC) confirmed by histology or cytology.

    2. Not received prior systemic treatment with stage IV, or recurrent NSCLC. Subjects who received adjuvant therapy are eligible if the adjuvant therapy was completed at least 12 months prior to the development of metastatic disease.

    3. PD-L1 TPS of less than 50% with 22C3 antibody.

    4. With at least one measurable lesion based on RECIST 1.1.

    5. Age of 75 years or older on the day of informed consent.

    6. ECOG Performance Status 0-1.

    7. Without activating mutation in EGFR or ALK chromosomal translocation.

    8. Absence of severe impairments of major organs.

    9. Life expectancy of 12 weeks or more from the treatment start date.

    10. Prior to the study registration, able to provide written informed consent after a thorough explanation of the study content.

    Exclusion Criteria:
    1. Before the first dose of trial treatment:

    Had major surgery (<3 weeks prior to the first dose)

    1. Received radiation therapy to the lung that exceeds 30 Gy within 6 months of the first dose of the study treatment.

    2. Completed palliative radiotherapy within 7 days of the first dose of the treatment.

    3. Has received a live-virus vaccination within 30 days of planned treatment initiation.

    Seasonal flu vaccines that do not contain live virus are permitted.

    1. Has clinically active diverticulitis, intra-abdominal abscess, GI obstruction, peritoneal carcinomatosis.

    2. Has a history of malignancy except if the subject has undergone curative therapy without recurrence for 5 years since initiation of that therapy.

    3. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

    4. Previously had a severe hypersensitivity reaction to treatment with another mAb.

    5. Has a known sensitivity to any component of pemetrexed

    6. Has active autoimmune disease that has required systemic treatment in past 2 years

    7. Is on chronic systemic steroids. Subjects with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study.

    8. Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin.

    9. Is unable or unwilling to take folic acid or vitamin B12 supplementation.

    10. Had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms.

    11. Has an active infection requiring therapy.

    12. Has a history of Human Immunodeficiency Virus (HIV)

    13. Has known active Hepatitis B or C. Active Hepatitis B is defined as a known positive HBsAg result.

    14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the Principal Investigator.

    15. Has symptomatic ascites or pleural effusion.

    16. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.

    17. Patients wishing their partner to become pregnant during the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Hospital Organization Nagoya Medical Center Nagoya Aichi Japan 460-0001

    Sponsors and Collaborators

    • National Hospital Organization Nagoya Medical Center
    • Central Japan Lung Study Group
    • Merck Sharp & Dohme LLC

    Investigators

    • Principal Investigator: Yoshihito Kogure, MD, PhD, National Hospital Organization Nagoya Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    National Hospital Organization Nagoya Medical Center
    ClinicalTrials.gov Identifier:
    NCT04396457
    Other Study ID Numbers:
    • NMC-CJLSG1901
    First Posted:
    May 20, 2020
    Last Update Posted:
    Apr 26, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 26, 2021